References
- Cooper DL, Doria R, Salloum E. Primary gastrointestinal lymphomas. Gastroenterologist. 1996;4(1):54–64.
- Ghimire P, Wu GY, Zhu L. Primary gastroin-testinal lymphoma. World J Gastroenterol. 2011;17(6):697–707. doi: 10.3748/wjg.v17.i6.697
- O'Malley DP, Goldstein NS, Banks PM. The recognition and classification of lymphoproliferative disorders of the gut. Hum Pathol. 2014;45(5):899–916. doi: 10.1016/j.humpath.2013.12.001
- Amer MH, El-Akkad S. Gastrointestinal lymphoma in adults: clinical features and management of 300 cases. Gastroenterology. 1994;106(4):846–58.
- Stolte M. Helicobacter pylori gastritis and gastric MALT-lymphoma. Lancet. 1992;339(8795):745–6. doi: 10.1016/0140-6736(92)90645-J
- Leslie LA, Lebwohl B, Neugut AI, Gregory MJ, Bhagat G, Green PH. Incidence of lymphoproliferative disorders in patients with celiac disease. Am J Hematol. 2012;87(8):754–759. doi: 10.1002/ajh.23237
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi: 10.1016/j.cell.2011.02.013
- Hisaoka M, Matsuyama A, Hashimoto H. Aberrant MAD2 expression in soft-tissue sarcoma. Pathol Int. 2008;58(6):329–333. doi: 10.1111/j.1440-1827.2008.02232.x
- Kato T, Daigo Y, Aragaki M, Ishikawa K, Sato M, Kondo S, et al. Overexpression of MAD2 predicts clinical outcome in primary lung cancer patients. Lung Cancer. 2011;74(1):124–131. doi: 10.1016/j.lungcan.2011.01.025
- Li L, Xu DB, Zhao XL, Hao TY. Combination analysis of Bub1 and Mad2 expression in endometrial cancer: act as a prognostic factor in endometrial cancer. Arch Gynecol Obstet. 2013;288(1):155–165. doi: 10.1007/s00404-012-2706-7
- Choi JW, Kim Y, Lee JH, Kim YS. High expression of spindle assembly checkpoint proteins CDC20 and MAD2 is associated with poor prognosis in urothelial bladder cancer. Virchows Arch. 2013;463(5):681–687. doi: 10.1007/s00428-013-1473-6
- Dawson IMP, Cornes JS, Morson BC. Primary malignant lymphoid tumors of the intestinal tract. Report of 37 cases with a study of factors influencing prognosis. Br J Surg. 1961;49(1):80–89. doi: 10.1002/bjs.18004921319
- Musshoff K. Clinical staging classification of non-Hodgkin's lymphomas. Strahlentherapie. 1997;153(4):218–221.
- Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–586. doi: 10.1200/JCO.2006.09.2403
- Howell JM, Auer-Grzesiak I, Zhang J, Andrews CN, Stewart D, Urbanski SJ. Increasing incidence rates, distribution and histological characteristics of primary gastrointestinal non-Hodgkin lymphoma in a North American population. Can J Gastroenterol. 2012;26(7):452–456.
- Cheung MC, Housri N, Ogilvie MP, Sola JE, Koniaris LG. Surgery does not adversely affect survival in primary gastrointestinal lymphoma. J Surg Oncol. 2009;100(1):59–64. doi: 10.1002/jso.21298
- Fischbach W. Gastrointestinal lymphomas: the Wurzburg study experience. Recent Results Cancer Res. 2000;156:134–140. doi: 10.1007/978-3-642-57054-4_17
- Han JS, Holland AJ, Fachinetti D, Kulukian A, Cetin B, Cleveland DW. Catalytic assembly of the mitotic checkpoint inhibitor BubR1-Cdc20 by a Mad2-induced functional switch in Cdc20. Mol Cell. 2013;51(1):92–104. doi: 10.1016/j.molcel.2013.05.019
- Sotillo R, Hernando E, Diaz-Rodriguez E, Teruya-Feldstein J, Cordon-Cardo C, Lowe SW, et al. Mad2 Overexpression promotes aneuploidy and tumorigenesis in mice. Cancer Cell. 2007;11(1):9–23. doi: 10.1016/j.ccr.2006.10.019
- Gemma A, Hosoya Y, Seike M, Uematsu K, Kurimoto F, Hibino S, et al. Genomic structure of the human MAD2 gene and mutation analysis in human lung and breast cancers. Lung Cancer. 2001;32(3):289–295. doi: 10.1016/S0169-5002(00)00223-3
- Sotillo R, Schvartzman JM, Socci ND, Benezra R. Mad2-induced chromosome instability leads to lung tumour relapse after oncogene withdrawal. Nature. 2010;464(7287):436–440. doi: 10.1038/nature08803
- Yu L, Liu S, Guo W, Zhang B, Liang Y, Feng Q. Upregulation of Mad2 facilitates in vivo and in vitro osteosarcoma progression. Oncol Rep. 2012;28(6):2170–2176.